Identification of anti-CD16a single domain antibodies and their application in bispecific antibodies

References

• Reusch U, Burkhardt C, Fucek I, Le Gall F, Le Gall M, Hoffmann K, Knackmuss SH, Kiprijanov S, Little M, Zhukovsky EA. 2014. A novel tetravalent bispecific tandab (cd30/cd16a) efficiently recruits nk cells for the lysis of cd30+ tumor cells. MAbs. 6(3):728–739. doi:10.4161/mabs.28591.
   PubMed Web of Science ®Google Scholar
• Mandelboim OMP, Davis DM, Jo CH, Boyson JE, Strominger JL. Human cd16 as a lysis receptor mediating direct natural killer cell cytotoxicity. Proc Natl Acad Sci USA. 1999;96:5640–5644. doi:10.1073/pnas.96.10.5640.
   PubMedGoogle Scholar
• Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fermeaux V, Bertheau P, Garnier J, et al.. 2006. Trastuzumab-based treatment of her2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?. Br J Cancer. 94(2):259–267. doi:10.1038/sj.bjc.6602930
   PubMed Web of Science ®Google Scholar
• Ejaz AA, Asmar A, Alsabbagh MM, Ahsan N. 2012. Rituximab in immunologic glomerular diseases. MAbs. 4(2):198–207. doi:10.4161/mabs.4.2.19286.
   PubMed Web of Science ®Google Scholar
• Alderson KL, Sondel PM. 2011. Clinical cancer therapy by nk cells via antibody-dependent cell-mediated cytotoxicity. J Biomed Biotechnol. 2011:379123. doi:10.1155/2011/379123.
   PubMedGoogle Scholar
• Bowles JA, Wang SY, Link BK, Allan B, Beuerlein G, Campbell MA, Marquis D, Ondek B, Wooldridge JE, Smith BJ, et al.. 2006. Anti-cd20 monoclonal antibody with enhanced affinity for cd16 activates nk cells at lower concentrations and more effectively than rituximab. Blood. 108(8):2648–2654. doi:10.1182/blood-2006-04-020057
   PubMed Web of Science ®Google Scholar
• Oppenheim DE, Spreafico R, Etuk A, Malone D, Amofah E, Pena-Murillo C, Murray T, McLaughlin L, Choi BS, Allan S, et al.. 2014. Glyco-engineered anti-egfr mab elicits adcc by nk cells from colorectal cancer patients irrespective of chemotherapy. Br J Cancer. 110(5):1221–1227. doi:10.1038/bjc.2014.35
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. 2002. Therapeutic activity of humanized anti-cd20 monoclonal antibody and polymorphism in igg fc receptor fcgammariiia gene. Blood. 99(3):754–758. doi:10.1182/blood.V99.3.754.
   PubMed Web of Science ®Google Scholar
• Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. 1997. Fc gammariiia-158v/f polymorphism influences the binding of igg by natural killer cell fc gammariiia, independently of the fc gammariiia-48l/r/h phenotype. Blood. 90(3):1109–1114. doi:10.1016/S0165-2478(97)85823-3.
   PubMed Web of Science ®Google Scholar
• Fan G, Wang Z, Hao M, Li J. 2015. Bispecific antibodies and their applications. J Hematol Oncol. 8:130. doi:10.1186/s13045-015-0227-0.
   PubMed Web of Science ®Google Scholar
• van Spriel AB, van Ojik HH, van De Winkel JG. 2000. Immunotherapeutic perspective for bispecific antibodies. Immunol Today. 21(8):391–397. doi:10.1016/S0167-5699(00)01659-5.
   PubMedGoogle Scholar
• Arndt MA, Krauss J, Kipriyanov SM, Pfreundschuh M, Little M. A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human hodgkin’s tumors. Blood. 1999;94(8):2562–2568.
   PubMed Web of Science ®Google Scholar
• McCall AM, Shahied L, Amoroso AR, Horak EM, Simmons HH, Nielson U, Adams GP, Schier R, Marks JD, Weiner LM. 2001. Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity. J Immunol. 166(10):6112–6117. doi:10.4049/jimmunol.166.10.6112.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhou C, Li J, Liu J, Lin L, Li L, Cao D, Li Q, Wang Z. 2018. Single domain based bispecific antibody, muc1-bi-1, and its humanized form, muc1-bi-2, induce potent cancer cell killing in muc1 positive tumor cells. PLoS One. 13(1):e0191024. doi:10.1371/journal.pone.0191024.
   PubMed Web of Science ®Google Scholar
• Dong B, Zhou C, He P, Li J, Chen S, Miao J, Li Q, Wang Z. 2016. A novel bispecific antibody, biss, with potent anti-cancer activities. Cancer Biol Ther. 17(4):364–370. doi:10.1080/15384047.2016.1139266.
   PubMed Web of Science ®Google Scholar
• Oak E, Bartlett NL. 2015. Blinatumomab for the treatment of b-cell lymphoma. Expert Opin Investig Drugs. 24(5):715–724. doi:10.1517/13543784.2015.1021415.
   PubMed Web of Science ®Google Scholar
• Amann M, Friedrich M, Lutterbuese P, Vieser E, Lorenczewski G, Petersen L, Brischwein K, Kufer P, Kischel R, Baeuerle PA, et al.. 2009. Therapeutic window of an epcam/cd3-specific bite antibody in mice is determined by a subpopulation of epcam-expressing lymphocytes that is absent in humans. Cancer Immunol Immunother. 58(1):95–109. doi:10.1007/s00262-008-0529-y
   PubMed Web of Science ®Google Scholar
• Clynes RA, Desjarlais JR. 2018. Redirected t cell cytotoxicity in cancer therapy. Annu Rev Med. doi:10.1146/annurev-med-062617-035821
   PubMed Web of Science ®Google Scholar
• Oikawa S, Nakazato H, Kosaki G. 1987. Primary structure of human carcinoembryonic antigen (cea) deduced from cdna sequence. Biochem Biophys Res Commun. 142(2):511–518. doi:10.1016/0006-291X(87)90304-4.
   PubMed Web of Science ®Google Scholar
• Peng L, Oberst MD, Huang J, Brohawn P, Morehouse C, Lekstrom K, Baeuerle PA, Wu H, Yao Y, Coats SR, et al.. 2012. The cea/cd3-bispecific antibody medi-565 (mt111) binds a nonlinear epitope in the full-length but not a short splice variant of cea. PLoS One. 7(5):e36412. doi:10.1371/journal.pone.0036412
   PubMed Web of Science ®Google Scholar
• Hammarstrom S. 1999. The carcinoembryonic antigen (cea) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol. 9(2):67–81. doi:10.1006/scbi.1998.0119.
   PubMed Web of Science ®Google Scholar
• Hong H, Sun J, Cai W. 2008. Radionuclide-based cancer imaging targeting the carcinoembryonic antigen. Biomark Insights. 3:435–451. doi:10.4137/BMI.S1124.
   PubMedGoogle Scholar
• Goldenberg DM, Wlodkowski TJ, Sharkey RM, Silberstein EB, Serafini AN, Garty II, Van Heertum RL, Higginbotham-Ford EA, Kotler JA, Balasubramanian N, et al.. 1993. Colorectal cancer imaging with iodine-123-labeled cea monoclonal antibody fragments. J Nucl Med. 34(1):61–70. doi:10.1097/00004728-199301000-00010
   PubMed Web of Science ®Google Scholar
• Moffat FL Jr., Pinsky CM, Hammershaimb L, Petrelli NJ, Patt YZ, Whaley FS, Goldenberg DM. 1996. Clinical utility of external immunoscintigraphy with the immu-4 technetium-99m fab’ antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase iii trial. The immunomedics study group. J Clin Oncol. 14(8):2295–2305. doi:10.1200/JCO.1996.14.8.2295.
   PubMed Web of Science ®Google Scholar
• Rozan C, Cornillon A, Petiard C, Chartier M, Behar G, Boix C, Kerfelec B, Robert B, Pelegrin A, Chames P, et al.. 2013. Single-domain antibody-based and linker-free bispecific antibodies targeting fcgammariii induce potent antitumor activity without recruiting regulatory t cells. Mol Cancer Ther. 12(8):1481–1491. doi:10.1158/1535-7163.MCT-12-1012
   PubMed Web of Science ®Google Scholar
• Kuroki M, Hachimine K, Huang J, Shibaguchi H, Kinugasa T, Maekawa S, Kuroki M. 2005. Re-targeting of cytotoxic t lymphocytes and/or natural killer cells to cea-expressing tumor cells with anti-cea antibody activity. Anticancer Res. 25(6A):3725–3732. doi:10.1063/1.1146580.
   PubMed Web of Science ®Google Scholar
• Li L, He P, Zhou C, Jing L, Dong B, Chen S, Zhang N, Liu Y, Miao J, Wang Z, et al.. 2015. A novel bispecific antibody, s-fab, induces potent cancer cell killing. J Immunother. 38(9):350–356. doi:10.1097/CJI.0000000000000099
   PubMed Web of Science ®Google Scholar
• Rossotti MA, Gonzalez-Techera A, Guarnaschelli J, Yim L, Camacho X, Fernandez M, Cabral P, Leizagoyen C, Chabalgoity JA, Gonzalez-Sapienza G. 2015. Increasing the potency of neutralizing single-domain antibodies by functionalization with a cd11b/cd18 binding domain. MAbs. 7(5):820–828. doi:10.1080/19420862.2015.1068491.
   PubMed Web of Science ®Google Scholar
• Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, Bendahman N, Hamers R. 1993. Naturally occurring antibodies devoid of light chains. Nature. 363(6428):446–448. doi:10.1038/363446a0.
   PubMed Web of Science ®Google Scholar
• Nanobodies: MS. 2013. Natural single-domain antibodies. Annu Rev Biochem. 82:775–797. doi:10.1146/annurev-biochem-063011-092449.
   PubMed Web of Science ®Google Scholar
• Arezumand R, Alibakhshi A, Ranjbari J, Ramazani A, Muyldermans S. 2017. Nanobodies as novel agents for targeting angiogenesis in solid cancers. Front Immunol. 8:1746. doi:10.3389/fimmu.2017.01746.
   PubMed Web of Science ®Google Scholar
• Muyldermans S, Baral TN, Retamozzo VC, De Baetselier P, De Genst E, Kinne J, Leonhardt H, Magez S, Nguyen VK, Revets H, et al.. 2009. Camelid immunoglobulins and nanobody technology. Vet Immunol Immunopathol. 128(1–3):178–183. doi:10.1016/j.vetimm.2008.10.299
   PubMed Web of Science ®Google Scholar
• Li J, Zhou C, Dong B, Zhong H, Chen S, Li Q, Wang Z. 2016. Single domain antibody-based bispecific antibody induces potent specific anti-tumor activity. Cancer Biol Ther. 17(12):1231–1239. doi:10.1080/15384047.2016.1235659.
   PubMed Web of Science ®Google Scholar
• Behar G, Siberil S, Groulet A, Chames P, Pugniere M, Boix C, Sautes-Fridman C, Teillaud JL, Baty D. 2008. Isolation and characterization of anti-fcgammariii (cd16) llama single-domain antibodies that activate natural killer cells. Protein Eng Des Sel. 21(1):1–10. doi:10.1093/protein/gzm064.
   PubMed Web of Science ®Google Scholar
• Stewart CS, MacKenzie CR, Hall JC. 2007. Isolation, characterization and pentamerization of alpha-cobrotoxin specific single-domain antibodies from a naive phage display library: preliminary findings for antivenom development. Toxicon. 49(5):699–709. doi:10.1016/j.toxicon.2006.11.023.
   PubMed Web of Science ®Google Scholar
• Shahsavarian MA, Le Minoux D, Matti KM, Kaveri S, Lacroix-Desmazes S, Boquet D, Friboulet A, Avalle B, Padiolleau-Lefevre S. 2014. Exploitation of rolling circle amplification for the construction of large phage-display antibody libraries. J Immunol Methods. 407:26–34. doi:10.1016/j.jim.2014.03.015.
   PubMed Web of Science ®Google Scholar
• Vincke C, Gutierrez C, Wernery U, Devoogdt N, Hassanzadeh-Ghassabeh G, Muyldermans S. 2012. Generation of single domain antibody fragments derived from camelids and generation of manifold constructs. Methods Mol Biol. 907:145–176. doi:10.1007/978-1-61779-974-7_8.
   PubMedGoogle Scholar
• Sharifzadeh Z, Rahbarizadeh F, Shokrgozar MA, Ahmadvand D, Mahboudi F, Rahimi Jamnani F, Aghaee Bakhtiari SH. 2013. Development of oligoclonal nanobodies for targeting the tumor-associated glycoprotein 72 antigen. Mol Biotechnol. 54(2):590–601. doi:10.1007/s12033-012-9601-0.
   PubMed Web of Science ®Google Scholar